JP6419195B2 - モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療 - Google Patents

モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療 Download PDF

Info

Publication number
JP6419195B2
JP6419195B2 JP2016546191A JP2016546191A JP6419195B2 JP 6419195 B2 JP6419195 B2 JP 6419195B2 JP 2016546191 A JP2016546191 A JP 2016546191A JP 2016546191 A JP2016546191 A JP 2016546191A JP 6419195 B2 JP6419195 B2 JP 6419195B2
Authority
JP
Japan
Prior art keywords
treatment
allergic rhinitis
olopatadine
nasal
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016546191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531949A (ja
JP2016531949A5 (enExample
Inventor
ニーリマ・カイラトカー・ジョシ
アブヘイ・クルカルニ
ディネシュ・プラディープ・ウェール
ヴィクラム・マンシング・ボセール
ピユシュ・アガルワル
パトリック・コヘイン
スディーシュ・ケー・タントリー
チャド・オー
Original Assignee
グレンマーク・スペシャルティー・エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グレンマーク・スペシャルティー・エスエー filed Critical グレンマーク・スペシャルティー・エスエー
Publication of JP2016531949A publication Critical patent/JP2016531949A/ja
Publication of JP2016531949A5 publication Critical patent/JP2016531949A5/ja
Application granted granted Critical
Publication of JP6419195B2 publication Critical patent/JP6419195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016546191A 2013-10-04 2014-10-03 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療 Active JP6419195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3174MUM2013 2013-10-04
IN3174MU2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076047A Division JP6768733B2 (ja) 2013-10-04 2018-04-11 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Publications (3)

Publication Number Publication Date
JP2016531949A JP2016531949A (ja) 2016-10-13
JP2016531949A5 JP2016531949A5 (enExample) 2016-11-24
JP6419195B2 true JP6419195B2 (ja) 2018-11-07

Family

ID=51982657

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016546191A Active JP6419195B2 (ja) 2013-10-04 2014-10-03 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP2018076047A Active JP6768733B2 (ja) 2013-10-04 2018-04-11 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP2020028523A Pending JP2020097624A (ja) 2013-10-04 2020-02-21 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018076047A Active JP6768733B2 (ja) 2013-10-04 2018-04-11 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP2020028523A Pending JP2020097624A (ja) 2013-10-04 2020-02-21 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Country Status (21)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP2922553B1 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN112773808A (enExample)
ES (1) ES3071407T3 (enExample)
FI (1) FI2922553T3 (enExample)
HK (1) HK1215674A1 (enExample)
HR (1) HRP20260742T1 (enExample)
LT (1) LT2922553T (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302A1 (enExample)
PL (1) PL2922553T3 (enExample)
PT (1) PT2922553T (enExample)
RS (1) RS68262B1 (enExample)
RU (1) RU2686670C2 (enExample)
SI (1) SI2922553T1 (enExample)
SM (1) SMT202600244T1 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018123157A (ja) * 2013-10-04 2018-08-09 グレンマーク・スペシャルティー・エスエー モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN115444851A (zh) * 2017-06-28 2022-12-09 格兰马克专业公司 用于治疗鼻炎的分配装置和药物组合物
CN111787954B (zh) * 2018-02-23 2023-09-05 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
EP1227812B1 (en) 1999-10-08 2007-04-18 Schering Corporation Topical nasal treatment using desloratadine and mometasone furoate
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
CA2504200A1 (en) * 2002-11-12 2004-05-27 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
PL1814538T3 (pl) 2004-11-24 2010-02-26 Alcon Inc Sposób dostarczania donosowego sprayu
PT1919450E (pt) * 2005-09-01 2014-09-10 Meda Ab Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados
EP1968548A2 (en) 2005-12-02 2008-09-17 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
RU2434652C2 (ru) 2006-04-21 2011-11-27 Токо Якухин Когио Кабусики Кайся Емкость для текучей среды и система безвоздушного дозирования текучей среды с использованием упомянутой емкости
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
EP2318049A1 (en) * 2008-07-15 2011-05-11 Schering Corporation Intranasal compositions comprising a decongestant and a corticosteroid
US8642069B2 (en) 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
BR112012001169A2 (pt) 2009-07-17 2016-03-01 Alcon Res Ltd sistema de pulverização nasal de olopatadina para crianças
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
JP5683719B2 (ja) 2011-01-04 2015-03-11 イスタ・ファーマシューティカルズ・インコーポレイテッドＩｓｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ベポタスチン組成物
CN104755615A (zh) 2012-10-25 2015-07-01 诺维信公司 用于餐具洗涤的改进的方法
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
UA116793C2 (uk) 2013-09-13 2018-05-10 Гленмарк Спешіалті С.А. Стабільна фармацевтична композиція з фіксованою дозою, що містить мометазон й олопатадин
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018123157A (ja) * 2013-10-04 2018-08-09 グレンマーク・スペシャルティー・エスエー モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Also Published As

Publication number Publication date
ES3071407T3 (es) 2026-06-23
LT2922553T (lt) 2026-07-10
EP4272839A3 (en) 2024-01-03
RS68262B1 (en) 2026-07-31
WO2015049665A1 (en) 2015-04-09
MY176808A (en) 2020-08-21
JP2018123157A (ja) 2018-08-09
ZA201504740B (en) 2016-10-26
RU2015128496A3 (enExample) 2018-06-19
US20150099725A1 (en) 2015-04-09
PH12015502302B1 (en) 2016-02-15
PH12015502302A1 (en) 2016-02-15
EP2922553A1 (en) 2015-09-30
SI2922553T1 (sl) 2026-07-31
UA120587C2 (uk) 2020-01-10
PL2922553T3 (pl) 2026-07-13
PT2922553T (pt) 2026-06-05
JP2016531949A (ja) 2016-10-13
HRP20260742T1 (hr) 2026-07-31
CN112773808A (zh) 2021-05-11
JP2020097624A (ja) 2020-06-25
MX2015009429A (es) 2015-10-09
CN105792828A (zh) 2016-07-20
RU2015128496A (ru) 2017-11-13
JP6768733B2 (ja) 2020-10-14
SMT202600244T1 (it) 2026-07-16
US10646500B2 (en) 2020-05-12
RU2019104453A (ru) 2019-03-28
RU2686670C2 (ru) 2019-04-30
FI2922553T3 (fi) 2026-06-15
MX2020003035A (es) 2020-07-22
HK1215674A1 (zh) 2016-09-09
EP2922553B1 (en) 2026-05-06
EP4272839A2 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
JP6768733B2 (ja) モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
Hebert et al. Once‐daily mometasone furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an active‐and placebo‐controlled study
EP2799071B1 (en) Levocetirizine and montelukast for the treatment of influenza and common cold
US8642069B2 (en) Composition and method for treating colds
Giger et al. Comparison of once-versus twice-daily use of beclomethasone dipropionate aqueous nasal spray in the treatment of allergic and non-allergic chronic rhinosinusitis
Newson-Smith et al. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis
TW201016209A (en) Intranasal compositions, dosage forms and methods of treatments
MX2010012234A (es) Cc10 humana recombinante y composiciones del mismo para uso en el tratamiento de rinitis nasal.
Lumry et al. Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily
Okubo et al. Efficacy and safety of the emedastine patch, a novel transdermal drug delivery system for allergic rhinitis: phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel-group comparative study in patients with seasonal allergic rhinitis
US10548907B2 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
EP2969001A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
JP2025510082A (ja) 経鼻オランザピン製剤およびその使用方法
Nathan Non-prescription medicines
LaForce et al. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis.
WO2020132263A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
HK40095786A (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
RU2799761C2 (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
JP7391026B2 (ja) モメタゾン及びオロパタジンの組み合わせを用いた小児対象におけるアレルギー性鼻炎の治療
KR20230018481A (ko) 질병의 치료를 위한 2-(다이에틸아미노)에틸 2-(4-아이소부틸페닐)프로피오네이트의 국소 투여
Parikh et al. A Randomized Comparative Study of “New Nasivion Care Drops” in Patients with Nasal Congestion Due to Acute Exacerbation of Allergic Rhinitis
WO2023177328A1 (en) Bisamide derivative of dicarboxylic acid for use in restoring the external respiratory function after coronavirus infection
Langade A Randomized Comparative Study of" New Nasivion Care Drops" in Patients with Nasal Congestion Due to Acute Exacerbation of...
Higgins Benefits of new formulation of triamcinolone?
Morton Leukotriene receptor antagonists in childhood asthma

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181009

R150 Certificate of patent or registration of utility model

Ref document number: 6419195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250